Beneficial Ownership Report · SCHEDULE 13G
Haemonetics Corporation
HAENYSEEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Haemonetics Corporation
- Company CIK
- 0000313143
- Street
- 125 SUMMER STREET
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02110
Statement details
- Security class
- Common stock, $.01 par value per share
- Event date
- 02/24/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- North Peak Capital Management, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Aggregate amount owned
- 2,370,495.00
- Percent of class
- 5.1
- Sole voting power
- 0.00
- Shared voting power
- 1,882,037.00
- Sole dispositive power
- 488,458.00
- Shared dispositive power
- 1,882,037.00
- Aggregate excludes certain shares
- N
- Comments
- The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common stock, $.01 par value per share ("Common Stock") of Haemonetics Corporation (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on February 5, 2026.
Reporting person 2
- Name
- North Peak Capital GP, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Aggregate amount owned
- 1,882,037.00
- Percent of class
- 4.0
- Sole voting power
- 0.00
- Shared voting power
- 1,882,037.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,882,037.00
- Aggregate excludes certain shares
- N
- Comments
- The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 3
- Name
- North Peak Capital Partners, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 135,354.00
- Percent of class
- 0.3
- Sole voting power
- 0.00
- Shared voting power
- 135,354.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 135,354.00
- Aggregate excludes certain shares
- N
- Comments
- The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 4
- Name
- North Peak Capital Partners II, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 993,566.00
- Percent of class
- 2.1
- Sole voting power
- 0.00
- Shared voting power
- 993,566.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 993,566.00
- Aggregate excludes certain shares
- N
- Comments
- The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 5
- Name
- North Peak Capital Alpha Fund, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 651,061.00
- Percent of class
- 1.4
- Sole voting power
- 0.00
- Shared voting power
- 651,061.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 651,061.00
- Aggregate excludes certain shares
- N
- Comments
- The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 6
- Name
- North Peak Capital Ultra Fund, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 102,056.00
- Percent of class
- 0.2
- Sole voting power
- 0.00
- Shared voting power
- 102,056.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 102,056.00
- Aggregate excludes certain shares
- N
- Comments
- The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 7
- Name
- Michael Kevin Kahan
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 1,882,037.00
- Percent of class
- 4.0
- Sole voting power
- 0.00
- Shared voting power
- 1,882,037.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,882,037.00
- Aggregate excludes certain shares
- N
- Comments
- The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Reporting person 8
- Name
- Jeremy Steven Kahan
- Citizenship / organization
- X1
- Reporting person type
- HC · CO
- Aggregate amount owned
- 1,882,037.00
- Percent of class
- 4.0
- Sole voting power
- 0.00
- Shared voting power
- 1,882,037.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,882,037.00
- Aggregate excludes certain shares
- N
- Comments
- The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
Item 1
Issuer
Haemonetics Corporation
Principal executive office address
125 SUMMER STREET, BOSTON, MA, 02110
Item 2
Citizenship
See Item 4 on the cover page(s) hereto.
Filing person
This statement is jointly filed by and on behalf of each of North Peak Capital Management, LLC, a Delaware limited liability company ("North Peak Management"), North Peak Capital GP, LLC, a Delaware limited liability company ("North Peak GP"), North Peak Capital Partners, LP, a Delaware limited partnership ("Fund I"), North Peak Capital Partners II, LP, a Delaware limited partnership ("Fund II"), North Peak Capital Alpha Fund, LP, a Delaware limited partnership ("Alpha Fund"), North Peak Capital Ultra Fund, LP, a Delaware limited partnership ("Ultra Fund"), Jeremy S. Kahan and Michael K. Kahan (each, a "Reporting Person" and collectively, the "Reporting Persons"). North Peak Management is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. North Peak Management is also an investment adviser to a separately managed account of an advisory client and may be deemed to beneficially own securities directly in such separately managed account, but North Peak Management does not have any voting authority with respect to any securities in such separately managed account. North Peak GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. Messrs. Kahan are the co-managers of, and each may be deemed to indirectly beneficially own securities beneficially owned by, each of North Peak Management and North Peak GP. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock held directly by the other Reporting Persons. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
Principal business or residence address
The address of the principal business office of each of the Reporting Persons is c/o North Peak Capital Management, LLC, 405 Lexington Avenue, Suite 5001, New York, NY 10174.
Item 3
Not applicable indication
Y
Item 4
Percent of class
See Item 11 on the cover page(s) hereto.
Amount beneficially owned
See Item 9 on the cover page(s) hereto.
Sole voting power
See Item 5 on the cover page(s) hereto.
Shared voting power
See Item 6 on the cover page(s) hereto.
Sole dispositive power
See Item 7 on the cover page(s) hereto.
Shared dispositive power
See Item 8 on the cover page(s) hereto.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Exhibits
Exhibit 99.1 Joint Filing Agreement (filed herewith)
Signature 1
- Reporting person
- North Peak Capital Management, LLC
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Managing Member
- Date
- 03/03/2026
Signature 2
- Reporting person
- North Peak Capital GP, LLC
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Manager
- Date
- 03/03/2026
Signature 3
- Reporting person
- North Peak Capital Partners, LP
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
- Date
- 03/03/2026
Signature 4
- Reporting person
- North Peak Capital Partners II, LP
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
- Date
- 03/03/2026
Signature 5
- Reporting person
- North Peak Capital Alpha Fund, LP
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
- Date
- 03/03/2026
Signature 6
- Reporting person
- North Peak Capital Ultra Fund, LP
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
- Date
- 03/03/2026
Signature 7
- Reporting person
- Michael Kevin Kahan
- Signed
- /s/ Michael Kahan
- Title
- Michael Kahan
- Date
- 03/03/2026
Signature 8
- Reporting person
- Jeremy Steven Kahan
- Signed
- /s/ Jeremy Kahan
- Title
- Jeremy Kahan
- Date
- 03/03/2026
Filed exhibits
- JOINT FILING AGREEMENT ↗ea027953601ex99-1.htm
Company context
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.